New study shows castle biosciences' decisiondx®-melanoma test outperforms staging and cp-gep in identifying patients at low risk of sentinel lymph node positivity

Patients identified as low risk by decisiondx-melanoma had a 2.8% sentinel lymph node (sln) positivity rate, well below the national comprehensive cancer network® (nccn) guidelines' 5% threshold to forgo sentinel lymph node biopsy (slnb) surgery friendswood, texas, april 30, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced the publication of a new study in cancer diagnosis & prognosis demonstrating that decisiondx-melanoma outperforms both american joint committee on cancer (ajcc) staging and the cp-gep test (clinicopathological and gene expression profiling model) in identifying patients at low risk of sln positivity who may consider forgoing slnb surgery.1 “when relying on genomic testing to guide critical decisions about procedures like slnb, a test must demonstrate exceptional accuracy in identifying patients with minimal risk of metastasis," said peter a. prieto, m.d.
CSTL Ratings Summary
CSTL Quant Ranking